Diyabetik Obezlerde Eksenatidin Metabolik ve İnflamatuar Belirteçler Üzerine Etkisi

Year 2025, Volume: 5 Issue: 3, 96 - 100, 29.07.2025

Eşref Araç , Mahsun Çağlin

https://doi.org/10.56016/dahudermj.1653914

https://izlik.org/JA37ZB94PU

Abstract

Amaç: Bu çalışma, diyabetik obez bireylerde eksenatid tedavisinin metabolik ve inflamatuar belirteçler üzerindeki etkilerini değerlendirmeyi amaçlamaktadır.
Yöntem: Çalışma, 01 Temmuz 2013 ile 31 Aralık 2019 tarihleri arasında Dicle Üniversitesi Hastanelerinde tedavi gören, yaşları 18-90 arasında değişen, Tip 2 diyabet ve obezite tanısı almış 119 hastanın retrospektif analizini içermektedir. Hastaların eksenatid tedavisi öncesi ve 6 ay sonraki metabolik ve inflamatuar belirteçleri karşılaştırılmıştır.
Bulgular: Hastaların yaş ortalaması 52.26±8.93 olup, %17.6'sı erkek ve %82.4'ü kadındır. Eksenatid tedavisi sonrasında LDH/albümin ve CRP/albümin oranlarında anlamlı düşüşler gözlenmiştir (p<0.05). Ayrıca, kan glukoz ve HbA1c düzeylerinde de belirgin azalmalar tespit edilmiştir.
Sonuç: Eksenatid tedavisi, diyabetik obez hastalarda metabolik ve inflamatuar belirteçler üzerinde olumlu etkiler göstermektedir. Özellikle albümin seviyelerindeki iyileşme ve CRP ile LDH düzeylerindeki düşüşler dikkat çekicidir. Eksenatid, bu hasta grubunda kronik hastalık yönetiminde ve komplikasyonların önlenmesinde önemli bir rol oynayabilir.

Keywords

Tip 2 diyabet , obezite , eksenatid , metabolik belirteçler , inflamatuar belirteçler.

Ethical Statement

Ethical approval was obtained from the Dicle University Ethics Committee (Approval Number: 2023/296), and the study was conducted in accordance with the Declaration of Helsinki.

Effect of Exenatide on Metabolic and Inflammatory Markers in Diabetic Obese Patients

https://izlik.org/JA37ZB94PU

Abstract

Background: This study aimed to evaluate the effects of exenatide treatment on metabolic and inflammatory markers in patients with type 2 diabetes and obesity.
Methods: This retrospective study included 119 patients diagnosed with type 2 diabetes and obesity who were treated at Dicle University Hospital between July 1, 2013, and December 31, 2019. Patients’ metabolic and inflammatory markers before and after 6 months of exenatide treatment were compared.
Results: The mean age of the patients was 52.26±8.93 years; 17.6% were male, and 82.4% were female. After 6 months of exenatide treatment, significant decreases were observed in the LDH/albumin and CRP/albumin ratios (p<0.05) fasting glucose (160.5 ± 35.2 to 135.8 ± 28.9 mg/dL), HbA1c (8.5 ± 1.2% to 7.2 ± 1.1%), and BMI (34.5 ± 4.2 to 32.8 ± 3.9 kg/m²) (p<0.05). Comorbidities like hypertension and dyslipidemia also showed improvement.
Conclusion: Exenatide treatment demonstrated favorable effects on both metabolic and inflammatory markers in diabetic obese patients. These findings suggest that exenatide may play a beneficial role in the management of chronic inflammation and metabolic control in this patient group.

Keywords

Type 2 diabetes , obesity , exenatide , inflammation , metabolic markers

Ethical Statement

Ethical approval was obtained from the Dicle University Ethics Committee (Approval Number: 2023/296), and the study was conducted in accordance with the Declaration of Helsinki.

References

• World Health Organization. Global report on diabetes. WHO; 2016.
• Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006 Dec 14;444(7121):860-867. doi: 10.1038/nature05485.
• Oral A, Küçük C, Köse M. Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study. Journal of Clinical Medicine. 2024; 13(20):6121. https://doi.org/10.3390/jcm13206121
• Naveirinho J, Pereira JA, Guimarães JT, Carvalho D. GLP-1 receptor agonists and inflammation: a review. Eur J Clin Pharmacol. 2016 Aug;72(8):915-23. doi: 10.1007/s00228-016-2081-1.
• Chan KM, Ladenson JH, Keefe JF. Creatine kinase isoenzyme activities in human serum. Clin Chem. 1978 Apr;24(4):682-685.
• American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023 Jan;46(Supplement_1):S1-S154 . doi: 10.2337/dc23-Sint.
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827.
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720.
• Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018 Feb 10;391(10120):541-551. doi: 10.1016/S0140-6736(17)33102-1.